Germany Endometriosis Pattern Changes; Prevalence and Therapy over 2010 and 2019 Years: A Retrospective Cross Sectional Study

Document Type : Original Article


1 Department of Gynecology and Obstetrics, Philipps University of Marburg, Marburg, Germany

2 Epidemiology, IQVIA, Frankfurt, Germany


Background: The aim of this study was to investigate whether the prevalence and the therapy patterns of endometriosis differ in 2010 and 2019. 
Materials and Methods: This retrospective cross-sectional study was based on the data from the IQVIA Disease Analyzer database and included women with at least one visit to one of the 136 private gynecologist practices in Germany in 2010 or 2019. The prevalence of endometriosis as well as prevalence of each endometriosis therapy such as Dienogest, other Progestins than Dienogest, and Gonadotropin-Releasing Hormones, was calculated in both years.
Results: The present study included 346,249 women documented in 2010 and 343,486 women documented in 2019. The prevalence of endometriosis increased from 0.53% in 2010 to 0.66% in 2019 (P<0.001). The proportion of endometriosis patients treated with Dienogest increased significantly between 2010 and 2019 (18.1 vs. 35.0%). The proportion of women prescribed other Progestins than Dienogest has not significantly changed between 2010 and 2019 (8.4 vs. 8.3%). Gonadotropin-releasing hormones were prescribed only rarely in both 2010 and 2019, with a significant decrease in prescriptions between these two years (3.7 vs. 2.0%).
Conclusion: There were significant changes in the prevalence and medical therapeutic patterns of endometriosis in 2010 versus 2019 reflecting changes in therapy guidelines and possibly in diagnostic methods.


1. Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020; 382(13): 1244-1256.
2. Gheorghisan-Galateanu AA, Gheorghiu ML. Hormonal therapy in women of reproductive age with endometriosis: an update. Acta Endocrinol (Buchar). 2019; 15(2): 276-281.
3. Rafique S, Decherney AH. Medical management of endometriosis. Clin Obstet Gynecol. 2017; 60(3): 485-496.
4. Guo SW. Endometriosis and ovarian cancer: potential benefits and harms of screening and risk-reducing surgery. Fertil Steril. 2015; 104(4): 813-830.
5. Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, et al. European society of human reproduction and embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014; 29(3): 400-412.
6. De Wilde RL, Alvarez J, Brölmann H, Campo R, Cheong Y, Lundorff P, et al. Adhesions and endometriosis: challenges in subfertility management: (an expert opinion of the ANGEL-the anti-adhesions in gynaecology expert panel-group). Arch Gynecol Obstet. 2016; 294(2): 299-301.
7. Falcone T, Flyckt R. Clinical management of endometriosis. Obstet Gynecol. 2018; 131(3): 557-571.
8. Greene AD, Lang SA, Kendziorski JA, Sroga-Rios JM, Herzog TJ, Burns KA. Endometriosis: where are we and where are we going? Reproduction. 2016; 152(3): 63-78.
9. Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017; 6(1): 34-41. 
10. Nisenblat V, Bossuyt PM, Shaikh R, Farquhar C, Jordan V, Scheffers CS, et al. Blood biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2016; 2016(5): 
11. Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K. Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther. 2018; 56(10):459-
12. Makiyan Z. Endometriosis origin from primordial germ cells. Organogenesis. 2017; 13(3): 95-102. 
13. Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al. Endometriosis. Endocr Rev. 2019; 40(4): 1048-1079.
14. Coccia ME, Rizzello F, Cammilli F, Bracco GL, Scarselli G. Endometriosis and infertility surgery and ART: an integrated approach for successful management. Eur J Obstet Gynecol Reprod Biol. 2008; 138(1): 54-59.
15. Burghaus S, Schäfer SD, Beckmann MW, Brandes I, Brünahl C, Chvatal R, et al. Diagnosis and treatment of endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF registry number 015/045, August 2020). Geburtshilfe Frauenheilkd. 2021; 81(4): 422-446.
16. Guerriero S, Saba L, Pascual MA, Ajossa S, Rodriguez I, Mais V, et al. Transvaginal ultrasound vs magnetic resonance imaging for diagnosing deep infiltrating endometriosis: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018; 51(5): 586-595.
17. Murji A, Biberoğlu K, Leng J, Mueller MD, Römer T, Vignali M, et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr Med Res Opin. 2020; 36(5): 895-907.
18. Klipping C, Duijkers I, Faustmann TA, Klein SF, Schuett B. Pharmacodynamic study of four oral dosages of dienogest. Fertil Steril.2010; 94(4): S181.
19. Shimizu Y, Mita S, Takeuchi T, Notsu T, Mizuguchi K, Kyo S. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids. 2011; 76(1-2): 60-67.
20. Hayashi A, Tanabe A, Kawabe S, Hayashi M, Yuguchi H, Yamashita Y, et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J Ovarian Res. 2012; 5(1):31.
21. Hee L, Kettner LO, Vejtorp M. Continuous use of oral contraceptives: an overview of effects and side-effects. Acta Obstet Gynecol Scand. 2013; 92(2): 125-136. 
22. Murji A, Biberoğlu K, Leng J, Mueller MD, Römer T, Vignali M, et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr Med Res Opin. 2020; 36(5): 895-907.